Overview
Phase I, open-label, dose-escalation and dose-expansion study evaluating the safety and efficacy of Universal Chimeric Antigen Receptor T-cell (UCART) targeting the Cluster of Differentiation 123 (CD123) in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety and clinical activity of Universal Chimeric Antigen Receptor T-cells targeting CD123 (UCART123v1.2) and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
Eligibility
Main Inclusion Criteria:
- Patients with relapsed or primary refractory AML (as defined in World Health Organization [WHO] criteria) with ≥5% bone marrow blasts
- Patients with CD123+ blast cells (verified by flow cytometry)
- Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of ≤1
- Adequate organ function, including bone marrow, renal, hepatic, pulmonary, and cardiac function based on the last assessment performed within screening period
- (Dose-escalation) Identified donor and transplant strategy prior to lymphodepletion (LD)
- Other criteria may apply
Main Exclusion Criteria:
- Patients with acute promyelocytic leukemia (APL) or central nervous system (CNS) Leukemia
- Previous investigation gene or cell therapy (including CAR)
- > 1 prior allogeneic stem cell transplantations (SCTs)
- Prior treatment with rituximab or other anti-cluster of differentiation 20 (anti-CD20) therapy within 3 months
- Any known active or uncontrolled infection
- Other criteria may apply